A model for identifying HERG K+ channel blockers

Bioorganic and Medicinal Chemistry

Volumn 12, Issue 9, 2004, Pages 2307-2315

  Aronov, Alex M ^a   Goldman, Brian B ^a  

^a VERTEX PHARMACEUTICALS   (United States)

Author keywords

AP, atom pairs; CAT, chemically advanced template; CoMFA, comparative molecular field analysis; HERG, human ether a go go related gene; LQTS, long QT syndrome; PDR, physicians' desk reference; QSAR, quantitative structure activity relationships

Indexed keywords

POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL HERG;

ACCURACY; ARTICLE; DRUG CLASSIFICATION; FILTER; MODEL; PHARMACOPHORE;

FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; HUMANS; LONG QT SYNDROME; MODELS, CHEMICAL;

EID: 1842686775     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2004.02.003     Document Type: Article

References (53)

1. Keating M.T., Sanguinetti M.C. Molecular genetic insights into cardiovascular disease. Science. 272:1996;681-685.
2. Viskin S. Long QT syndromes and torsade de pointes. Lancet. 354:1999;1625-1633.
3. Crumb W., Cavero I. QT interval prolongation by non-cardiovascular drugs: issues and solutions for novel drug development. Pharm. Sci. Technol. Today. 2:1999;270-280.
4. Trudeau M., Warmke J.W., Ganetzky B., Robertson G.A. HERG, a human inward rectifier in the voltage-gated potassium channel family. Science. 269:1995;92-95.
5. Sanguinetti M.C., Jiang C., Curran M.E., Keating M.T. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell. 81:1995;299-307.
6. Roti Roti E.C., Myers C.D., Ayers R.A., Boatman D.E., Delfosse S.A.et al. Interaction with GM130 during HERG ion channel trafficking. Disruption by type 2 congenital long QT syndrome mutations. J. Biol. Chem. 277:2002;47779-47785.
7. Paulussen A., Raes A., Matthijs G., Snyders D.J., Cohen N., Aerssens J. A novel mutation (T65P) in the PAS domain of the human potassium channel HERG results in the long QT syndrome by trafficking deficiency. J. Biol. Chem. 277:2002;48610-48616.
8. De Ponti F., Poluzzi E., Cavalli A., Recanatini M., Montanaro N. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsades de pointes: an overview. Drug Saf. 25:2002;263-286.
9. Ekins S., Crumb W.J., Sarazan R.D., Wikel J.H., Wrighton S.A. Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel. J. Pharmacol. Exp. Ther. 301:2002;427-434.
10. + channel blockers. J. Med. Chem. 45:2002;3844-3853.
11. Buyck, C.; Tollenaere, J.; Engels, M.; De Clerck, F. An in silico model for detecting potential hERG blocking. The 14th European Symposium on Quantitative Structure-Activity Relationships, 8-13 September 2002; Bournemouth, UK.
12. Roche O., Trube G., Zuegge J., Pflimlin P., Alanine A., Schneider G. A virtual screening method for prediction of the hERG potassium channel liability of compound libraries. ChemBioChem. 3:2002;455-459.
13. + channel. A model for bad behavior. J. Med. Chem. 46:2003;2017-2022.
14. Pearlstein R.A., Vaz R.J., Kang J., Chen X.-L., Preobrazhenskaya M., Shchekotikhin A.E., Korolev A.M., Lysenkova L.N., Miroshnikova O.V., Hendrix J., Rampe D. Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches. Bioorg. Med. Chem. Lett. 13:2003;1829-1835.
15. Mitcheson J.S., Chen J., Lin M., Culberson C., Sanguinetti M.C. A structural basis for drug-induced long QT syndrome. Proc. Natl. Acad. Sci. 97:2000;12329-12333.
16. Lees-Miller J.P., Duan Y., Teng G.Q., Duff H.J. Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in Xenopus oocytes: involvement of S6 sites. Mol. Pharmacol. 57:2000;367-374.
17. Chen J., Seebohm G., Sanguinetti M.C. Position of aromatic residues in the S6 domain, not inactivation, dictates cisapride sensitivity of HERG and eag potassium channels. Proc. Natl. Acad. Sci. 99:2002;12461-12466.
18. Doyle D.A., Morais Cabral J., Pfuetzner R.A., Kuo A., Gulbis J.M., Cohen S.L., Chait B.T., MacKinnon R. The structure of the potassium channel: molecular basis of K+ conduction and selectivity. Science. 280:1998;69-77.
19. Mason J.S., Good A.C., Martin E.J. 3-D pharmacophores in drug discovery. Curr. Pharm. Des. 7:2001;567-597.
20. Bradley E.K., Beroza P., Penzotti J.E., Grootenhuis P.D., Spellmeyer D.C., Miller J.L. A rapid computational method for lead evolution: description and application to alpha (1)-adrenergic antagonists. J. Med. Chem. 43:2000;2770-2774.
21. Penzotti J.E., Lamb M.L., Evensen E., Grootenhuis P.D. A computational ensemble pharmacophore model for identifying substrates of P-glycoprotein. J. Med. Chem. 45:2002;1737-1740.
22. Nilakantan R., Bauman N., Dixon J.S., Venkataraghavan R. Topological torsions: a new molecular descriptor for sar applications. Comparison with other descriptors. J. Chem. Inf. Comput. Sci. 27:1987;82-85.
23. Carhart R.E., Smith D.H., Venkataraghavan R. Atom pairs as molecular features in structure-activity studies: definition and application. J. Chem. Inf. Comput. Sci. 25:1985;64-73.
24. Schneider G., Neidhart W., Giller T., Schmid G. 'Scaffold-hopping' by topological pharmacophore search: a contribution to virtual screening. Angew. Chem., Int. Ed. 38:1999;2894-2896.
25. Daylight Chemical Information Software; Daylight Chemical Information: Mission Viejo, CA.
26. Zlokarnik, G. Vertex Pharmaceuticals, personal communication, 2003.
27. Friesen R.W., Ducharme Y., Ball R.G., Blouin M., Boulet L., Cote B., Frenette R., Girard M., Guay D., Huang Z.et al. Optimization of a tertiary alcohol series of phosphodiesterase-4 (PDE4) inhibitors: structure-activity relationship related to PDE4 inhibition and human ether-a-go-go related gene potassium channel binding activity. J. Med. Chem. 46:2003;2413-2426.
28. Kearsley S.K., Sallamack S., Fluder E.M., Andose J.D., Mosley R.T., Sheridan R.P. Chemical similarity using physiochemical property descriptors. J. Chem. Inf. Comput. Sci. 36:1996;118-127.
29. Schneider G. Trends in virtual combinatorial library design. Curr. Med. Chem. 9:2002;2095-2101.
30. Fenichel, R. R. http://fenichel.net/pages/Professional/subpages/QT/ Tables/pbydrug.htm.
31. Paul A.A., Witchel H.J., Hancox J.C. Inhibition of the current of heterologously expressed HERG potassium channels by flecainide and comparison with quinidine, propafenone, and lignocaine. Br. J. Pharmacol. 136:2002;717-729.
32. Volberg W.A., Koci B.J., Su W., Lin J., Zhou J. Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics. J. Pharmacol. Exp. Ther. 302:2002;320-327.
33. Witchel H.J., Pabbathi V.K., Hofmann G., Paul A.A., Hancox J.C. Inhibitory actions of the selective serotonin re-uptake inhibitor citalopram on HERG and ventricular L-type calcium currents. FEBS Lett. 512:2002;59-66.
34. Thomas D., Gut B., Wendt-Nordahl G., Kiehn J. The antidepressant drug fluoxetine is an inhibitor of human ether-a-go-go-related gene (HERG) potassium channels. J. Pharmacol. Exp. Ther. 300:2002;543-548.
35. Paul A.A., Leishman D.J., Witchel H.J., Hancox J.C. Effects of the class III antiarrhythmic agent dofetilide (UK-68,798) on L-type calcium current from rabbit ventricular myocytes. J. Pharm. Pharmacol. 53:2001;1671-1678.
36. O'Leary M.E. Inhibition of HERG potassium channels by cocaethylene: a metabolite of cocaine and ethanol. Cardiovasc. Res. 53:2002;59-67.
37. Potet F., Bouyssou T., Escande D., Baro I. Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether-a-gogo K (+) channel. J. Pharmacol. Exp. Ther. 299:2001;1007-1012.
38. Kamiya K., Mitcheson J.S., Yasui K., Kodama I., Sanguinetti M.C. Open channel block of HERG K (+) channels by vesnarinone. Mol. Pharmacol. 60:2001;244-253.
39. Shuba Y.M., Degtiar V.E., Osipenko V.N., Naidenov V.G., Woosley R.L. Testosterone-mediated modulation of HERG blockade by proarrhythmic agents. Biochem. Pharmacol. 62:2001;41-49.
40. Karle C.A., Kreye V.A., Thomas D., Rockl K., Kathofer S., Zhang W., Kiehn J. Antiarrhythmic drug carvedilol inhibits HERG potassium channels. Cardiovasc. Res. 49:2001;361-370.
41. Paul A.A., Witchel H.J., Hancox J.C. Inhibition of HERG potassium channel current by the class 1a antiarrhythmic agent disopyramide. Biochem. Biophys. Res. Commun. 280:2001;1243-1250.
42. O'Leary M.E. Inhibition of human ether-a-go-go potassium channels by cocaine. Mol. Pharmacol. 59:2001;269-277.
43. Gonzalez T., Longobardo M., Caballero R., Delpon E., Tamargo J., Valenzuela C. Effects of bupivacaine and a novel local anesthetic, IQB-9302, on human cardiac K+ channels. J. Pharmacol. Exp. Ther. 296:2001;573-583.
44. Taglialatela M., Pannaccione A., Castaldo P., Giorgio G., Annunziato L. Inhibition of HERG1 K(+) channels by the novel second-generation antihistamine mizolastine. Br. J. Pharmacol. 131:2000;1081-1088.
45. Bischoff U., Schmidt C., Netzer R., Pongs O. Effects of fluoroquinolones on HERG currents. Eur. J. Pharmacol. 406:2000;341-343.
46. Walker B.D., Singleton C.B., Tie H., Bursill J.A., Wyse K.R., Valenzuela S.M., Breit S.N., Campbell T.J. Comparative effects of azimilide and ambasilide on the human ether-a-go-go-related gene (HERG) potassium channel. Cardiovasc. Res. 48:2000;44-58.
47. Kreutner W., Hey J.A., Chiu P., Barnett A. Preclinical pharmacology of desloratadine, a selective and non-sedating histamine H1 receptor antagonist. Second communication: lack of central nervous system and cardiovascular effects. Arzneimittelforschung. 50:2000;441-448.
48. Cavero I., Mestre M., Guillon J.M., Crumb W. Drugs that prolong QT interval as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias. Expert Opin. Pharmacother. 1:2000;947-973.
49. Netzer R., Ebneth A., Bischoff U., Pongs O. Screening lead compounds for QT interval prolongation. Drug Discovery Today. 6:2001;78-84.
50. Egan W.J., Walters W.P., Murcko M.A. Guiding molecules towards drug-likeness. Curr. Opin. Drug Discov. Devel. 5:2002;540-549.
51. ®; Thompson Medical Economics: Montvale, NJ. http://www.pdrel.com.
52. Omega; OpenEye Scientific Software: Santa Fe, NM.
53. ACD/Labs; Advanced Chemistry Development: Toronto, Canada.